Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

NCT04270669 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age-Related Macular Degeneration

Interventions

BIOLOGICAL: intravitreal injection of RC28-E 0.5mg
BIOLOGICAL: intravitreal injection of RC28-E 1.0mg
BIOLOGICAL: intravitreal injection of RC28-E2.0mg

Sponsor

RemeGen Co., Ltd.